Rossi, John M.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 6,030

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 2,286

KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,862

Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels

Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 569

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 489

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 199

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Siddiqi, T., Jacobson, C. A., Westin, J. R., Chavez, J. C., Ghobadi, A., Herrera, A. F., LaCasce, A. S., et al. (2016) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 27

Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence

Chen, P.-H., Lipschitz, M., Wright, K., Armand, P., Jacobson, C. A., Roberts, Z. J., Rossi, J. M., Bot, A., Go, W. Y., & Rodig, S. J. (2018) · Blood

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 6